Amgen
Pays vs peer median
×1.04
+4% premium
Sample
23
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.10 | 19 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.50 | 9 |
| phase 2 | ×0.87 | 5 |
| phase 3 | ×1.04 | 4 |
| discovery | ×0.74 | 3 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | TIM-3-301 | Turning Point Therapeutics | GBM | discovery | $46M | $802M |
| 2025 | EGFR-301 | Arcus Biosciences | Ovarian | phase_1 | $239M | $2.3B |
| 2025 | NMDA-101 | Intra-Cellular Therapies | OCD | preclinical | $26M | $324M |
| 2025 | HTT | Prevail Therapeutics | Major Depressive Disorder | phase_3 | $278M | $2.5B |
| 2025 | CD19-301 | BioNTech | Cholangiocarcinoma | discovery | $31M | $385M |
| 2025 | Nectin-4-001 | Caribou Biosciences | DLBCL | phase_1 | $95M | $992M |
| 2025 | CEA-301 | Hengrui Medicine | Breast (TNBC) | discovery | $16M | $239M |
| 2025 | FRα-201 | Blueprint Medicines | Follicular Lymphoma | phase_3 | $150M | $1000M |
| 2025 | HER3-tinib | Junshi Biosciences | SCLC | discovery | $64M | $991M |
| 2025 | RET-201 | ORIC Pharmaceuticals | HCC | phase_2 | $314M | $2.7B |
| 2025 | Anti-CLDN18.2 | MacroGenics | HCC | discovery | $41M | $638M |
| 2025 | CD22-201 | Daiichi Sankyo | Mesothelioma | phase_1 | $78M | $989M |
| 2024 | Anti-KRAS G12D-301 | Replimune | Endometrial | phase_3 | $745M | $4.7B |
| 2024 | Anti-Amyloid-beta-stat | Prothena | Major Depressive Disorder | approved | $512M | $2.7B |
| 2024 | CD20-001 | RemeGen | DLBCL | discovery | $35M | $618M |
How this is computed
For each Amgen deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 23 disclosed deal premiums vs. peer medians. Raw premium 1.038, clamped to [0.7, 1.5].